trial
as of 2026-07-01Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics
NCTId NCT02573168
at a glance
— · Completed
Enrollment 103 (actual)
Sponsored by St. Joseph's Healthcare Hamilton
Primary completion 2019-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
103 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-01
Primary completion
2019-07
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
St. Joseph's Healthcare HamiltonLead Sponsor
Centre for Addiction and Mental HealthCollaborator
Genome CanadaCollaborator
AssureRx Canada LtdCollaborator
Assurex Health Inc.Collaborator
Investigators
3
Jean-Eric Tarride, PhDStudy Chair
James L Kennedy, MDPrincipal Investigator
Bryan Dechairo, PhDPrincipal Investigator
Sites
1 total
Toronto, Canada
Facts & assertions
4 sourced
Enrollment
103
Phase
NA
Primary Completion Date
2019-07
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
collaborator
indication
investigator